Myostatin inhibitors as pharmacological treatment for muscle wasting and muscular dystrophy
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Myostatin, a member of the transforming growth factor beta (TGF‐β) superfamily that is highly expressed in skeletal muscle, was first described in 1997. It has been known that loss of myostatin function induces an increase in muscle mass in mice, cow, dogs and humans. Therefore, myostatin and its receptor have emerged as a therapeutic target for loss of skeletal muscle such as sarcopenia and cachexia, as well as muscular dystrophies. At the molecular level, myostatin binds to and activates the activin receptor IIB (ActRIIB)/Alk 4/5 complex. Therapeutic approaches therefore are being taken both pre‐clinically and clinically to inhibit the myostatin signaling pathway. Several myostatin inhibitors, including myostatin antibodies, anti‐myostatin peptibody, activin A antibody, soluble (decoy) forms of ActRIIB (ActR II B‐Fc), anti‐myostatin adnectin, ActR II B antibody have been tested in the last decade. The aim of this review is to present the current knowledge of several myostatin inhibitors as a therapeutic approach for patients with loss of skeletal muscle.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Double muscling in cattle due to mutations in the myostatin gene
McPherron, A. C., & Lee, S.-J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.23.12457 · Cited by 2,039 · cited 1×
“Myostatin is expressed almost exclusively in cells of the skeletal muscle lineage in humans, and evidence indicates that myostatin acts as an essential negative regulator of muscle bulk [3].”
BackgroundA deletion in the bovine myostatin gene causes the double–muscled phenotype in cattle
Grobet, L., Royo Martin, L. J., Poncelet, D., Pirottin, D., Brouwers, B., Riquet, J., Schoeberlein, A., Dunner, S., Ménissier, F., Massabanda, J., et al. (1997) · Nature Genetics · doi:10.1038/ng0997-71 · Cited by 1,556
Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child
Schuelke, M., Wagner, K. R., Stolz, L. E., Hübner, C., Riebel, T., Kömen, W., Braun, T., Tobin, J. F., & Lee, S.-J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040933 · Cited by 1,399
Clop, A., Marcq, F., Takeda, H., Pirottin, D., Tordoir, X., Bibé, B., Bouix, J., Caiment, F., Elsen, J.-M., Eychenne, F., et al. (2006) · Nature Genetics · doi:10.1038/ng1810 · Cited by 1,260
An overview of sarcopenia: facts and numbers on prevalence and clinical impact
von Haehling, S., Morley, J. E., & Anker, S. D. (2010) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-010-0014-2 · Cited by 888 · cited 1×
“Cachexia in chronic disease Cachexia is a syndrome occurring at terminal stages of diseases such as cancer, chronic heart failure, chronic kidney disease, or chronic pulmonary obstructive disease [27,28].”
BackgroundSelf-citationFunctional improvement of dystrophic muscle by myostatin blockade
Bogdanovich, S., Krag, T. O. B., Barton, E. R., Morris, L. D., Whittemore, L.-A., Ahima, R. S., & Khurana, T. S. (2002) · Nature · doi:10.1038/nature01154 · Cited by 831
Mosher, D. S., Quignon, P., Bustamante, C. D., Sutter, N. B., Mellersh, C. S., Parker, H. G., & Ostrander, E. A. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030079 · Cited by 826
Suppression of body fat accumulation in myostatin-deficient mice
McPherron, A. C., & Lee, S.-J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0213562 · Cited by 505
Myostatin Knockout in Mice Increases Myogenesis and Decreases Adipogenesis
Lin, J., Arnold, H. B., Della-Fera, M. A., Azain, M. J., Hartzell, D. L., & Baile, C. A. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6500 · Cited by 313 · cited 1×
“Myostatin null mice had a decreased amount of adipose tissue [47,48].”
BackgroundLach-Trifilieff, E., Minetti, G. C., Sheppard, K., Ibebunjo, C., Feige, J. N., Hartmann, S., Brachat, S., Rivet, H., Koelbing, C., Morvan, F., et al. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01307-13 · Cited by 306
Cited by
Wilkinson, D. J., Piasecki, M., & Atherton, P. J. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.07.005 · Cited by 874
Kwak, J. Y., & Kwon, K.-S. (2019) · Annals of Geriatric Medicine and Research · doi:10.4235/agmr.19.0028 · Cited by 171
Review of WADA Prohibited Substances: Limited Evidence for Performance-Enhancing Effects
Heuberger, J. A. A. C., & Cohen, A. F. (2019) · Sports Medicine · doi:10.1007/s40279-018-1014-1 · Cited by 108
Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy
Wagner, K. R., Abdel-Hamid, H. Z., Mah, J. K., Campbell, C., Guglieri, M., Muntoni, F., Takeshima, Y., McDonald, C. M., Kostera-Pruszczyk, A., Karachunski, P., et al. (2020) · Neuromuscular Disorders · doi:10.1016/j.nmd.2020.05.002 · Cited by 67
Zebrafish models of sarcopenia
Daya, A., Donaka, R., & Karasik, D. (2020) · Disease Models & Mechanisms · doi:10.1242/dmm.042689 · Cited by 55
“So far, several studies have successfully established myostatin models to investigate the dual muscular phenotypes and translate the novel biological findings into drug discovery (Saitoh et al., 2017).”
Metadata
- Authors
- Saitoh, M., Ishida, J., Ebner, N., Anker, S. D., Springer, J., & von Haehling, S.
- Venue
- JCSM Clinical Reports
- Publisher
- Wiley
- Published
- 2017-01
- Volume
- 2
- Issue
- 1
- Pages
- 1-10
- ISSN
- 2521-3555 (ISSN-L)
- OpenAlex
- W2766098981
- Cited by
- 57
- References
- 13
- FWCI
- 2.43
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Myostatin inhibitors as pharmacological treatment for muscle wasting and muscular dystrophy. https://app.cochat.ai/papers/10.17987/jcsm-cr.v2i1.37
- The paper
- Saitoh, M., Ishida, J., Ebner, N., Anker, S. D., Springer, J., & von Haehling, S. (2017). Myostatin inhibitors as pharmacological treatment for muscle wasting and muscular dystrophy. JCSM Clinical Reports. https://doi.org/10.17987/jcsm-cr.v2i1.37
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.